Search

What’s Next for Leqembi After A Full Approval by the FDA

Listen to Dr. Keith Vossel’s exclusive interview with KNX News Radio, about the FDA’s full approval of the first-in-class Alzheimer’s drug, Lecanemab....

What Families Can Expect with the New FDA-Approved Alzheimer’s Medication, Leqembi

Watch Dr. Keith Vossel’s exclusive live interview with KNBC-LA, NBC Channel 4 News, about the FDA’s fully approved Alzheimer’s drug, Lecanemab....

Lecanemab, the New FDA-approved Drug for Patients with Early Alzheimer’s Disease (Segment 1 of 2)

Watch Dr. Keith Vossel’s exclusive live interview with KCAL-LA Evening News, about the benefits of the treatment, possible side effects, and expected costs...

Heavy Alcohol Intake May Worsen Cognitive Decline in Alzheimer’s Disease

Dr. Keith Vossel, Director of the Easton Center, commented on recent Alzheimer’s model research suggested long-term excessive intake of alcohol can...

Recent Paper Suggests That a New Blood Biomarker of Abnormal Astrocytes May Help Predict Alzheimer’s

Dr. Keith Vossel, Neurologist and Director of the Easton Center , was interviewed by Medical News about his viewpoint on early detection of abnormal astrocytes

Alzheimer’s and Brain Awareness Month

Dr. Keith Vossel's interview with Alex Cohen about raising awareness for Alzheimer’s and Brain Awareness Month with exciting updates in the Alzheimer’s field.

Genetic Testing for Frontotemporal Dementia

Dr. Keith Vossel, Neurologist and Director of the Easton Center , was interviewed by DailyMail about frontotemporal dementia.

Donanemab, Eli Lilly’s New Groundbreaking Alzheimer’s Drug

Dr. Keith Vossel, Director of the UCLA Easton Center, was interviewed by MarketWatch about Eli Lilly's new Alzheimer’s medication, donanemab.

New Study Suggests that a Catheter Ablation for Afib Could Reduce Risk of Cognitive Decline

The Uniqueness of Alzheimer's New Medication